Welcome to Visited Lingnan Modern Clinics In Surgery, Today is

Lingnan Modern Clinics In Surgery ›› 2022, Vol. 22 ›› Issue (06): 547-554.DOI: 10.3969/j.issn.1009-976X.2022.06.004

• Original Articles and Clinical Research • Previous Articles     Next Articles

The expression of miR-130b-3p in the blood of patients with non-small cell lung cancer and its potential significance

LI Jing-xiao1, LI Guo-sheng1, XU Yang1, HE Rong-quan2, ZHOU Hua-fu3, KONG Jin-liang4, CHEN Gang1   

  1. 1. Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China;
    2. Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China;
    3. Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China;
    4. Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
  • Contact: CHEN Gang, chengang@gxmu.edu.cn

MiR-130b-3p在非小细胞肺癌患者血液中的表达及潜在意义

李靖霄1, 李国盛1, 徐阳1, 何融泉2, 周华富3, 孔晋亮4, 陈罡1,*   

  1. 1.广西医科大学第一附属医院病理科,南宁 530021;
    2.广西医科大学第一附属医院肿瘤内科,南宁 530021;
    3.广西医科大学第一附属医院心胸外科,南宁 530021;
    4.广西医科大学第一附属医院呼吸内科,南宁 530021
  • 通讯作者: * 陈罡,Email:chengang@gxmu.edu.cn
  • 基金资助:
    广西医疗卫生适宜技术开发与推广应用项目(S2020031); 广西教育科学规划2021年度重点课题B类(2021B167)

Abstract: Objective This research aims to explore the expression and potential clinical significance of miR-130b-3p in the blood of NSCLC patients. Methods The Cancer Genome Atlas, Gene Expression Omnibus, and Sequence Read Archive were used to download NSCLC-associated miRNAs expression data, then the expression data of miR-130b-3p was extracted from included datasets. Estimating standardized mean difference (SMD) to comprehensively present the expression level of miR-130b-3p in the blood of NSCLC patients. A diagnostic test was performed to explore the discriminated potential of differentially expressed miR-130b-3p between NSCLC patients and healthy people. By making an interaction for predicted results from 12 databases in miRwalk 2.0, we screened out the downstream target genes of miR-130b-3p. Enrichment analysis was used to find potential signaling pathways of miR-130b-3p downstream target genes in regulating NSCLC development. Results A total of 300 blood samples from seven studies were included. MiR-130b-3p is downregulated in blood of NSCLC patients, including both LUAD (SMD=-1.45,95%CI: -2.66~-0.23) and LUSC (SMD=-0.46, 95%CI:-0.84~-0.09). The diagnostic test indicated miR-130b-3p has a good potential to discriminate NSCLC patients from healthy people AUC=0.85,95%CI:0.82~0.88). Forty-seven genes are identified as miR-130b-3p downstream targets, they significantly enrich in Renin-angiotensin system pathway. Conclusion MiR-130b-3p is downregulated in the blood of NSCLC patients and is expected to be used for early screening of NSCLC.

Key words: microRNA, MiR-130b-3p, non-small cell lung cancer, blood

摘要: 目的 探讨miR-130b-3p在NSCLC患者血液中的表达水平及潜在临床意义。方法 本研究使用癌症基因组图谱(TCGA)、基因表达谱数据库(GEO)以及序列片段归档数据库(SRA)下载了NSCLC相关的miRNAs表达谱,并提取miR-130b-3p在各个纳入的数据集中的表达量。计算标准化均数差(SMD)综合展示miR-130b-3p在NSCLC患者血液中的表达水平,进行诊断试验以探讨差异表达的miR-130b-3p对NSCLC患者和健康人的鉴别潜力。通过对miRwalk 2.0中12个数据库的预测结果进行交集,筛选出miR-130b-3p的下游靶基因,并采用富集分析探讨miR-130b-3p下游靶基因调控NSCLC的潜在信号通路。结果 共7项研究的300例NSCLC患者血液样本被纳入。miR-130b-3p在LUAD(SMD=-1.45,95%CI:-2.66~-0.23)以及LUSC(SMD=-0.46,95%CI:-0.84~-0.09)这两种NSCLC患者血液中的表达水平较对照组明显下调。诊断试验提示miR-130b-3p具有良好的区分NSCLC患者和健康人的潜力(AUC=0.85:95%CI:0.82~0.88)。47个基因被鉴定为miR-130b-3p的下游靶基因,这些靶基因显著富集于Renin-angiotensin system通路。结论 在NSCLC患者血液中表达下调的miR-130b-3p有望用于NSCLC的筛查。

关键词: 微小RNA, miR-130b-3p, 非小细胞肺癌, 血液

CLC Number: